Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases

Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's guest is Lynn Baranowski. Lynn is the CEO of Boston based, Avalon Pharma. The company is developing inhalable drugs for rare and severe lung diseases, such as pulmonary fibrosis and other interstitial lung diseases. Avolene has started with a couple of small molecules that are given orally and remade them into inhalable drugs so they can be more effectively delivered where they need to go, deep in the lungs. By concentrating delivery, the idea is that Avalon will be able to lower the doses needed and make treatments that are easier for patients to tolerate over the long term. In this episode, you'll hear Lynn's enthusiasm for developing better treatments for respiratory diseases. It's one of these therapeutic areas that doesn't capture a lot of news coverage, but lung diseases of one kind or another really affect many millions of people. Now before we get started, a word from the sponsor of the show, AlphaSense. Under unprecedented time and cost pressures, many life sciences teams have reached for off the shelf AI tools to stay afloat. Yet they have discovered that generic AI tools introduce new risks, such as hallucination. Tools that cannot withstand scientific or regulatory scrutiny are a liability in MLR review, portfolio committees, and investment decisions where every claim must be traceable to a source. More than isolated tools, teams need a purpose built intelligence layer designed for the rigor that the industry demands. Across life sciences functions, platforms like AlphaSense are streamlining the entire decision cycle. Go to timbermanreport.com for a link to download a report that covers the top AI use cases that have transformed how the industry's leading teams reach defensible answers. And quick question, when was the last time a CRO told you what something costs before you sign an NDA, sat through two scoping calls, and waited a week for a scope of work? In bioanalysis, pricing gets treated like a closely guarded secret. Dashbio thinks that's backward. It publishes pricing publicly on its website and even has a calculator that shows how the price changes if you redesign your study. You can see what your study costs before you talk to a human being. No surprise line items, no it depends, no games. Dash was built to be the bioanalysis company that's actually straightforward to work with, transparent pricing, guaranteed timelines, and data in days, not months. If you're tired of pricing that feels like a negotiation every single time, run your bioanalysis with Dash. Visit -.bio/pricing and see exactly how much your next bioanalysis study will cost. Now please enjoy this conversation with Lynn Baranowski on the long run. Lynn Baranowski, welcome to the long run. Hi, Luke. So happy to be here. Thanks for the invitation. Well, thanks for joining me today, Lynn. I'm I'm eager to get into this with you about respiratory drug development. And, you know, it all …